从“肾浊”论治甲状腺相关性眼病
Treatment of Thyroid Associated Ophthalmopathy from the Theory of “Kidney Turbidity”
摘要: 甲状腺相关性眼病是甲状腺与眼眶组织之间发生的免疫炎症反应,表现为眼外肌增粗、球后组织水肿、脂肪体积增多。中医药治疗甲状腺相关性眼病具有较好疗效,其辨治要点在目,而肾参与了目的形成发育及功能发挥,肾浊是甲状腺相关性眼病病变过程中的重要病理因素。肾浊为阴邪,其性秽浊、黏腻,容易阻滞气血津液运行输布,夹杂痰、湿、瘀为病,变化多端。治疗甲状腺相关性眼病时,可从肾浊的角度入手,在辨证选方的基础上,加以益肾泻浊。本文拟探讨“肾浊”理论在甲状腺相关性眼病治疗中的指导意义。
Abstract: Thyroid associated ophthalmopathy is an immune inflammatory reaction between the thyroid gland and the orbital tissue, manifested by thickening of the extraocular muscle, retrobulbar tis-sue edema, and increased fat volume. Traditional Chinese medicine-based treatment of thyroid associated ophthalmopathy has a good effect, and its key points are in the eye, while the kidney is involved in the formation, development and function. Kidney turbidity is an important pathological factor in the process of thyroid associated ophthalmopathy lesions. Kidney turbidity is Yin evil, which is turbid and sticky. Kidney turbidity can easily block the operation of qi, blood and body fluid. It can mix with phlegm, dampness and blood stasis for the disease, which would cause variability. Kidney turbidity is changeable. In the treatment of thyroid associated ophthalmopathy, we can start from the perspective of kidney turbidity, and benefit kidney diarrhea turbidity on the basis of syndrome differentiation. This paper intends to explore the guiding significance of the “kidney turbidity” theory in the treatment of thyroid associated ophthalmopathy.
文章引用:沈紫葳, 郑雅琴, 陈继东. 从“肾浊”论治甲状腺相关性眼病[J]. 中医学, 2023, 12(1): 210-214. https://doi.org/10.12677/TCM.2023.121034

参考文献

[1] 黄英志. 叶天士医学全书[M]. 北京: 中国中医药出版社, 1999: 341.
[2] 王新陆, 王栋先. 血浊的性质特点和辨证论治[J]. 天津中医药, 2020, 37(2): 148-152.
[3] 赵进喜, 庞博. 中医学“浊”的涵义及其临床意义[J]. 中医杂志, 2009, 50(7): 581-584.
[4] 朱文浩, 王栋先, 王新陆. 论“浊邪” [J]. 云南中医学院学报, 2015, 38(4): 28-30+47.
[5] 赵文霞. 国医大师张磊运用涤浊法治疗疑难病的经验[J]. 中华中医药杂志, 2021, 36(2): 831-833.
[6] 钱乙. 小儿药证直决[M]. 北京: 人民卫生出版社, 2017: 3.
[7] 田代华, 整理. 黄帝内经素问[M]. 北京: 人民卫生出版社, 2017: 20, 63.
[8] 辛海量, 张巧艳. 肾浊新说[J]. 时珍国医国药, 2017, 28(8): 1946-1947.
[9] 李经纬, 等. 中医大辞典[M]. 北京: 人民卫生出版社, 1995: 1028, 1328.
[10] 张介宾. 类经[M]. 北京: 中医古籍出版社, 2016: 543.
[11] 葆光道人. 秘传眼科龙木论[M]. 北京: 人民卫生出版社, 1986: 78.
[12] 周鸿飞, 李丹, 点校. 灵枢经[M]. 郑州: 河南科学技术出版社, 2017: 139.
[13] 王清任. 医林改错[M]. 北京: 人民卫生出版社, 2005, 14.
[14] 傅仁宇. 审视瑶函[M]. 北京: 中国医药科技出版社, 2018: 50, 67.
[15] 徐又芳. 中医五官科名著集成[M]. 北京: 华夏出版社, 1997: 339.
[16] 高龙, 张霞, 陈文信, 李红. Graves眼病活动期与非活动期分期辨治探讨[J]. 天津中医药大学学报, 2017, 36(5): 344-347.
[17] 张浩, 赵婧, 葛小宁, 董雅儒. 甲状腺相关性眼病的诊断性生物标志物研究进展[J]. 眼科新进展, 2022, 42(7): 562-567.
[18] 王秋怡, 符畅, 符茂雄, 林升雄. 血清TRAbIgG亚型在甲状腺相关性眼病患者中的特征及临床意义[J]. 临床和实验医学杂志, 2022, 21(4): 367-370.
[19] 蒋雅琳, 蒋敬庭. IGF受体检测在甲状腺相关性眼病中的临床意义[J]. 临床检验杂志, 2021, 39(12): 939-940.
[20] 何志伟, 胡欣, 陈国芳, 刘超. 甲状腺相关性眼病病因、发病机制及免疫靶向治疗的研究进展[J]. 山东医药, 2020, 60(28): 90-93.
[21] 姬璇, 张朝霞, 闫春芳, 孙斌. 甲状腺相关性眼病氧化应激反应的研究进展[J]. 中华眼科医学杂志, 2021, 11(2): 124-128.